Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  Bladder Cancer

  Free Subscription


1 Acta Oncol
1 Ann Surg Oncol
1 Anticancer Res
1 Arch Ital Urol Androl
2 Asian Pac J Cancer Prev
2 BMC Cancer
1 BMC Urol
2 Cancer Cytopathol
1 Cancer Prev Res (Phila)
1 Cell Rep Med
1 Clin Cancer Res
5 Clin Genitourin Cancer
2 Comput Math Methods Med
1 Curr Opin Urol
1 Eur Urol
1 Front Immunol
1 Front Med (Lausanne)
1 Front Oncol
2 Front Pharmacol
1 Front Psychol
1 Gan To Kagaku Ryoho
2 Hinyokika Kiyo
1 Infection
1 Int J Clin Oncol
1 Int J Mol Sci
1 Int J Surg
1 Int J Surg Pathol
1 Int J Urol
1 Int Urol Nephrol
1 J Anesth
1 J Cancer Res Ther
1 J Cell Mol Med
1 J Clin Oncol
1 J Immunother Cancer
1 J Pharm Biomed Anal
1 J Transl Med
1 Kidney360
1 Medicina (Kaunas)
1 Medicine (Baltimore)
1 Mol Carcinog
1 Molecules
1 Nat Commun
2 Nat Med
1 Oncogenesis
1 Oncologist
1 Open Med (Wars)
1 Radiat Oncol J
3 Sci Rep
1 Strahlenther Onkol
1 Support Care Cancer
1 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Oncol

  1. NORGAARD M, Mailhac A, Fagerlund K, Strunz-McKendry T, et al
    Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2020.
    Acta Oncol. 2023 Oct 3:1-7. doi: 10.1080/0284186X.2023.2263154.
    PubMed         Abstract available

    Ann Surg Oncol

  2. XU JH, Shao GZ, Yang YF, Fan ZQ, et al
    Comment on: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Sep 30. doi: 10.1245/s10434-023-14355.

    Anticancer Res

  3. SOMMER U, Grosser M, Aust D, Joehrens K, et al
    PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
    Anticancer Res. 2023;43:4365-4371.
    PubMed         Abstract available

    Arch Ital Urol Androl

  4. BETTOLI P, Liu Z, Jara N, Bakal F, et al
    Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network.
    Arch Ital Urol Androl. 2023;95:11533.
    PubMed         Abstract available

    Asian Pac J Cancer Prev

  5. BUDAYA TN, Permatasari HK, Widodo N, Prawiro SR, et al
    The Evolution of Polyclonal Antibody from Specific Epitope 47kDA for Detection of Bladder Cancer.
    Asian Pac J Cancer Prev. 2023;24:3155-3164.
    PubMed         Abstract available

  6. ASGARI M, Firouzi F, Abolhasani M, Bahadoram M, et al
    The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder.
    Asian Pac J Cancer Prev. 2023;24:3125-3131.
    PubMed         Abstract available

    BMC Cancer

  7. ALT M, Stecca C, Lin Y, Kazeem G, et al
    Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
    BMC Cancer. 2023;23:919.
    PubMed         Abstract available

  8. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    PubMed         Abstract available

    BMC Urol

  9. PAN G, Jiang B, Yi Z, Yin J, et al
    Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer.
    BMC Urol. 2023;23:155.
    PubMed         Abstract available

    Cancer Cytopathol

  10. GREENLAND NY, Khorsandi N, Peng Y, Balassanian R, et al
    Utility and performance of cell blocks in urine cytology: Experience at three teaching hospitals.
    Cancer Cytopathol. 2023;131:614-625.
    PubMed         Abstract available

  11. LEVY JJ, Chan N, Marotti JD, Kerr DA, et al
    Large-scale validation study of an improved semiautonomous urine cytology assessment tool: AutoParis-X.
    Cancer Cytopathol. 2023;131:637-654.
    PubMed         Abstract available

    Cancer Prev Res (Phila)

  12. RAO N, Starrett GJ, Piaskowski ML, Butler KE, et al
    Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
    Cancer Prev Res (Phila). 2023;16:561-570.
    PubMed         Abstract available

    Cell Rep Med

  13. KIM Y, Ju H, Yoo SY, Jeong J, et al
    Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer.
    Cell Rep Med. 2023 Sep 27:101224. doi: 10.1016/j.xcrm.2023.101224.
    PubMed         Abstract available

    Clin Cancer Res

  14. LI R, Sexton WJ, Dhillon J, Berglund A, et al
    A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
    Clin Cancer Res. 2023;29:3875-3881.
    PubMed         Abstract available

    Clin Genitourin Cancer

  15. GAMBA T, Paparo J, Panepinto O, Dionisio R, et al
    Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
    Clin Genitourin Cancer. 2023;21:509-516.
    PubMed         Abstract available

  16. FERRO M, Crocetto F, Tataru S, Barone B, et al
    Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2023;21:574-583.
    PubMed         Abstract available

  17. BAKALOUDI DR, Talukder R, Lin GI, Makrakis D, et al
    Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Clin Genitourin Cancer. 2023;21:584-593.
    PubMed         Abstract available

  18. JINDAL T, Zhang L, Deshmukh P, Reyes K, et al
    Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
    Clin Genitourin Cancer. 2023;21:e394-e404.
    PubMed         Abstract available

  19. PIERANTONI F, Dionese M, Basso U, Lai E, et al
    The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2023;21:e378-e385.
    PubMed         Abstract available

    Comput Math Methods Med

    Retracted: The Effect of Narrative Nursing Intervention on Shame in Elderly Patients with Bladder Cancer after Ileal Bladder Replacement: A Cohort Study.
    Comput Math Methods Med. 2023;2023:9761783.
    PubMed         Abstract available

    Retracted: MicroRNA-143-3p/TBX3 Axis Represses Malignant Cell Behaviors in Bladder Cancer.
    Comput Math Methods Med. 2023;2023:9763968.
    PubMed         Abstract available

    Curr Opin Urol

  22. CANCEL-TASSIN G, Koutros S
    Use of genomic markers to improve epidemiologic and clinical research in urology.
    Curr Opin Urol. 2023;33:414-420.
    PubMed         Abstract available

    Eur Urol

  23. FENG M, Matoso A, Epstein G, Fong M, et al
    Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://do
    Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.

    Front Immunol

  24. XIONG S, Li S, Zeng J, Nie J, et al
    Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Front Immunol. 2023;14:1253586.
    PubMed         Abstract available

    Front Med (Lausanne)

  25. WU Z, Feng Z, Wei H, Lin C, et al
    Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer.
    Front Med (Lausanne). 2023;10:1193133.
    PubMed         Abstract available

    Front Oncol

  26. FRERICHS LM, Frerichs B, Petzsch P, Kohrer K, et al
    Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells.
    Front Oncol. 2023;13:1228185.
    PubMed         Abstract available

    Front Pharmacol

  27. ZUO M, Chen H, Liao Y, He P, et al
    Sulforaphane and bladder cancer: a potential novel antitumor compound.
    Front Pharmacol. 2023;14:1254236.
    PubMed         Abstract available

  28. WANG X, Pan J, Guan Q, Ren N, et al
    Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer.
    Front Pharmacol. 2023;14:1215296.
    PubMed         Abstract available

    Front Psychol

  29. YANG J, Tan Y, Yao C
    Study on anxiety, depression, and subjective wellbeing of patients with bladder cancer in their different chemotherapy stages.
    Front Psychol. 2023;14:1226712.
    PubMed         Abstract available

    Gan To Kagaku Ryoho

  30. SEKIGUCHI Y, Nishimura Y, Kanda H, Kawamura M, et al
    A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder Cancer.
    Gan To Kagaku Ryoho. 2023;50:985-992.
    PubMed         Abstract available

    Hinyokika Kiyo

  31. HATTORI Y, Kato M, Imamura T, Inaba S, et al
    [Idiopathic Thrombocytopenia Purpura After Pembrolizumab Treatment Against Locally Recurrent Bladder Cancer : A Case Report].
    Hinyokika Kiyo. 2023;69:255-258.
    PubMed         Abstract available

  32. KIM CJ, Ide H, Nakamura M, Hanada E, et al
    [Occurrence of Distant Metastasis During Bladder Presevation in T1 high-grade Bladder Cancer: Report of Three Cases].
    Hinyokika Kiyo. 2023;69:249-254.
    PubMed         Abstract available


  33. MANCIULLI T, Marangoni D, Salas-Coronas J, Bocanegra C, et al
    Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature.
    Infection. 2023;51:1185-1221.
    PubMed         Abstract available

    Int J Clin Oncol

  34. NISHIYAMA H, Tsuzuki T, Ohyama C, Matsuyama H, et al
    Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
    Int J Clin Oncol. 2023;28:1398-1410.
    PubMed         Abstract available

    Int J Mol Sci

  35. LU XJ, Lai HF, Wu SC, Chen CL, et al
    Elucidating the Associated Biological Function and Clinical Significance of RHOJ Expression in Urothelial Carcinoma.
    Int J Mol Sci. 2023;24:14081.
    PubMed         Abstract available

    Int J Surg

  36. ZHONG W, Xia K, Liu L, Cheng S, et al
    Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
    Int J Surg. 2023;109:2742-2750.
    PubMed         Abstract available

    Int J Surg Pathol

  37. DANESHPAJOUHNEJAD P, Morrison C, Zhao X, Daniel RE, et al
    Primary Alveolar Soft-Part Sarcoma (ASPS) of the Prostate: Report of a Deceptive Case.
    Int J Surg Pathol. 2023;31:1359-1363.
    PubMed         Abstract available

    Int J Urol

    Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
    Int J Urol. 2023;30:859.

    Int Urol Nephrol

  39. KAYAR R, Bastug Y, Tokuc E, Topaktas R, et al
    Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
    PubMed         Abstract available

    J Anesth

  40. KONDO Y, Nagamine Y, Yoshikawa N, Echigo N, et al
    Incidence of perioperative hypotension in patients undergoing transurethral resection of bladder tumor after oral 5-aminolevulinic acid administration: a retrospective multicenter cohort study.
    J Anesth. 2023;37:703-713.
    PubMed         Abstract available

    J Cancer Res Ther

  41. ZAIDI N, Siddiqui Z, Sankhwar SN, Srivastava AN, et al
    Urinary microRNA-10a levels in diagnosis and prognosis of urinary bladder cancer.
    J Cancer Res Ther. 2023;19:1324-1329.
    PubMed         Abstract available

    J Cell Mol Med

  42. LIU Y, Pang ZQ, Wang JS, Wang JF, et al
    Heat shock protein family A member 8 is a prognostic marker for bladder cancer: Evidences based on experiments and machine learning.
    J Cell Mol Med. 2023 Sep 28. doi: 10.1111/jcmm.17977.
    PubMed         Abstract available

    J Clin Oncol

  43. KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
    Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
    J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
    PubMed         Abstract available

    J Immunother Cancer

  44. SONG Y, Peng Y, Qin C, Wang Y, et al
    Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    J Immunother Cancer. 2023;11:e006643.
    PubMed         Abstract available

    J Pharm Biomed Anal

  45. ROSLAN A, Said DS, Sulaiman N, Mohd Ghani KA, et al
    Cluster of differentiation 147 (CD147) as potential membrane protein biomarker for bladder cancer cells.
    J Pharm Biomed Anal. 2023;236:115729.
    PubMed         Abstract available

    J Transl Med

  46. ZHENG J, Lu S, Huang Y, Chen X, et al
    Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.
    J Transl Med. 2023;21:685.
    PubMed         Abstract available


  47. COTE G, Alqaisi H, Chan CT, Jiang DM, et al
    Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma.
    Kidney360. 2023;4:e1203-e1211.
    PubMed         Abstract available

    Medicina (Kaunas)

  48. YOO D, Min KW, Pyo JS, Kim NY, et al
    Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ.
    Medicina (Kaunas). 2023;59:1609.
    PubMed         Abstract available

    Medicine (Baltimore)

  49. CHALHOUB IG, Boulos RT, Dagher YG, El Helou S, et al
    Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study.
    Medicine (Baltimore). 2023;102:e34562.
    PubMed         Abstract available

    Mol Carcinog

  50. WANG M, Zhang C, Ying Y, Hua M, et al
    PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of bladder cancer.
    Mol Carcinog. 2023 Oct 3. doi: 10.1002/mc.23643.
    PubMed         Abstract available


  51. ZHANG X, Hu X, Xie Y, Xie L, et al
    Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration.
    Molecules. 2023;28:6720.
    PubMed         Abstract available

    Nat Commun

  52. MOREO E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, et al
    Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.
    Nat Commun. 2023;14:6090.
    PubMed         Abstract available

    Nat Med

  53. LI R
    Organ-sparing precision treatment for muscle-invasive bladder cancer.
    Nat Med. 2023 Oct 4. doi: 10.1038/s41591-023-02575.

  54. GALSKY MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, et al
    Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02568.
    PubMed         Abstract available


  55. WANG G, He X, Dai H, Lin L, et al
    WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2.
    Oncogenesis. 2023;12:47.
    PubMed         Abstract available


  56. PEAK T, Spiess PE, Li R, Grivas P, et al
    Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry.
    Oncologist. 2023;28:e910-e920.
    PubMed         Abstract available

    Open Med (Wars)

  57. WU T, Li N, Wu X, Du Y, et al
    LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer.
    Open Med (Wars). 2023;18:20230788.
    PubMed         Abstract available

    Radiat Oncol J

  58. VIEIRA HM, Kasper DP, Wang R, Smith LM, et al
    Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer.
    Radiat Oncol J. 2023;41:154-162.
    PubMed         Abstract available

    Sci Rep

  59. NAKAMURA M, Tsuru I, Izumi T, Ono A, et al
    Advantages of enhanced recovery after surgery program in robot-assisted radical cystectomy.
    Sci Rep. 2023;13:16237.
    PubMed         Abstract available

  60. INOUE Y, Yamada T, Fujihara A, Miyashita M, et al
    Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study.
    Sci Rep. 2023;13:16580.
    PubMed         Abstract available

  61. YAN H, Zhang L, Li R
    Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and immunotherapy biomarker through bladder cancer clinical data validation and pan-cancer analysis.
    Sci Rep. 2023;13:16457.
    PubMed         Abstract available

    Strahlenther Onkol

  62. TORON M, Woloszyn A
    [Organ-sparing treatment of node-positive bladder cancer].
    Strahlenther Onkol. 2023 Sep 29. doi: 10.1007/s00066-023-02156.

    Support Care Cancer

  63. OKADA M, Shindo T, Fujino K, Maeda T, et al
    Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.
    Support Care Cancer. 2023;31:607.
    PubMed         Abstract available

    World J Urol

  64. HUSSEIN AA, Bhat TA, Jing Z, Gomez EC, et al
    Does the urinary microbiome profile change after treatment of bladder cancer?
    World J Urol. 2023 Oct 5. doi: 10.1007/s00345-023-04627.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.